Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The Phase III failure of the high-profile Alzheimer's disease drug dimebon is a setback not only for Alzheimer's drug development, but also for Pfizer, which very much needs pipeline successes to offset upcoming patent losses, and for Medivation, whose near-term future hinges on the drug

You may also be interested in...



Will Cabazitaxel Success Derail Other Prostate Cancer Trials?

The release of positive Phase III results for Sanofi-Aventis' next-generation chemotherapy agent cabazitaxel in hormone-resistant prostate cancer could put a damper on recruitment for clinical trials of other late-stage drug trials in the same indication

J&J And Elan Strike A Deal On Key Alzheimer's Disease Assets

Six months after announcing it was looking at strategic alternatives, Elan's beleaguered management has found a way to address its challenges: It announced July 2 that it is selling its Alzheimer's immunotherapy program (AIP), which includes the high-profile Alzheimer's disease drug bapineuzumab and all related assets, to Johnson & Johnson for what essentially amounts to $500 million in the near-term and a commitment from J&J to buy an 18.4 percent stake in Elan for $1 billion

Pfizer Finds Backup For Aricept In Medivation’s Dimebon

Medivation Alzheimer’s candidate is unique for its disease-modifying potential.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel